{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:41:00Z","timestamp":1792644060044,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82560674"],"award-info":[{"award-number":["82560674"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016079","name":"Science and Technology Department of Xinjiang Uygur Autonomous Region","doi-asserted-by":"publisher","award":["2025A03006"],"award-info":[{"award-number":["2025A03006"]}],"id":[{"id":"10.13039\/100016079","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016079","name":"Science and Technology Department of Xinjiang Uygur Autonomous Region","doi-asserted-by":"publisher","award":["2025A03006-1"],"award-info":[{"award-number":["2025A03006-1"]}],"id":[{"id":"10.13039\/100016079","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejmech.2026.119315","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:38:55Z","timestamp":1788849535000},"page":"119315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design, synthesis, and screening of novel thienopyrimidine derivatives as PI3K\/HDAC dual inhibitors against cervical cancer cells"],"prefix":"10.1016","volume":"320","author":[{"given":"Weixu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naziyila","family":"Shayilan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xijin","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7022-6318","authenticated-orcid":false,"given":"Cheng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejmech.2026.119315_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2026.119315_bib2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ijgo.70277","article-title":"Cancer of the cervix uteri: 2025 update","volume":"171","author":"Bhatla","year":"2025","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119315_bib3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"18","key":"10.1016\/j.ejmech.2026.119315_bib4","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.2174\/092986711796011193","article-title":"Present and future of PI3K pathway inhibition in cancer: perspectives and limitations","volume":"18","author":"Ciraolo","year":"2011","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119315_bib5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1021\/ml1001932","article-title":"Synthesis and in vitro and in vivo evaluation of Phosphoinositide-3-kinase inhibitors","volume":"2","author":"Burger","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119315_bib6","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1073\/pnas.0712169105","article-title":"Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms","volume":"105","author":"Zhao","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119315_bib7","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/1078-0432.CCR-20-3652","article-title":"FDA approval summary: alpelisib plus fulvestrant for patients with HR\u2013positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer","volume":"27","author":"Narayan","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"1715","key":"10.1016\/j.ejmech.2026.119315_bib8","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.58347\/tml.2024.1715f","article-title":"Inavolisib (Itovebi) for locally advanced or metastatic breast cancer","volume":"66","year":"2024","journal-title":"Med. Lett. Drugs Ther."},{"issue":"20","key":"10.1016\/j.ejmech.2026.119315_bib9","doi-asserted-by":"crossref","first-page":"21282","DOI":"10.1021\/acs.jmedchem.5c01164","article-title":"Discovery of 2-(4-Ureido-piperidin-1-yl)-4-morpholinothieno [3,2-d] pyrimidines as orally bioavailable Phosphoinositide-3-Kinase inhibitors with in vitro and in Vivo Antitumor efficacy in triple-negative breast cancer","volume":"68","author":"Mohammed","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119315_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111718","article-title":"Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer","volume":"183","author":"Elmenier","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119315_bib11","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1021\/acs.jmedchem.7b00357","article-title":"Design, synthesis, and biological evaluation of dimorpholine-substituted thienopyrimidines as potential class I PI3K\/mTOR dual inhibitors","volume":"60","author":"Zhan","year":"2017","journal-title":"J. Med. Chem."},{"issue":"17","key":"10.1016\/j.ejmech.2026.119315_bib12","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.1021\/jm300717c","article-title":"Potent and highly selective benzimidazole inhibitors of PI3-kinase delta","volume":"55","author":"Murray","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119315_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115915","article-title":"Discovery of benzamide-based PI3K\/HDAC dual inhibitors with marked pro-apoptosis activity in lymphoma cells","volume":"262","author":"Deng","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119315_bib14","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC inhibitors in cancer development and therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ejmech.2026.119315_bib15","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1186\/s12885-015-1967-5","article-title":"The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and wildtype non-small cell lung cancer cells","volume":"15","author":"Greve","year":"2015","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.ejmech.2026.119315_bib16","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.18632\/oncotarget.659","article-title":"Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance","volume":"3","author":"McCubrey","year":"2012","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119315_bib17","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3390\/ph19010130","article-title":"Phosphatidylinositol-3-Kinase (PI3K) and histone deacetylase (HDAC) multitarget inhibitors: an update on clinical and preclinical candidates","volume":"19","author":"Lima","year":"2026","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119315_bib18","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41420-025-02470-4","article-title":"The dual HDAC\/PI3K inhibitor CUDC-907 inhibits the growth and proliferation of MYC-driven Group 3 medulloblastoma","volume":"11","author":"Gou","year":"2025","journal-title":"Cell Death Discov."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119315_bib19","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1007\/s40265-025-02248-z","article-title":"Ifupinostat: first approval","volume":"85","author":"Fung","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119315_bib20","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.exphem.2018.12.007","article-title":"Compounds targeting class II histone deacetylases do not cause panHDACI-associated impairment of megakaryocyte differentiation","volume":"72","author":"Simic","year":"2019","journal-title":"Exp. Hematol."},{"issue":"13","key":"10.1016\/j.ejmech.2026.119315_bib21","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1007\/s00018-012-0921-9","article-title":"Multiple roles of class I HDACs in proliferation, differentiation, and development","volume":"69","author":"Reichert","year":"2012","journal-title":"Cell. Mol. Life Sci."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119315_bib22","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.3390\/cancers15082222","article-title":"The emerging role of histone deacetylase inhibitors in cervical cancer therapy","volume":"15","author":"Psilopatis","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"19","key":"10.1016\/j.ejmech.2026.119315_bib23","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.3390\/cells11193161","article-title":"Pathological role of HDAC8: cancer and beyond","volume":"11","author":"Kim","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2026.119315_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116972","article-title":"HDAC8 as a target in drug discovery: function, structure and design","volume":"280","author":"Zhao","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119315_bib25","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/leu.2008.9","article-title":"A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T\u2013cell lymphomas","volume":"22","author":"Balasubramanian","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2026.119315_bib26","unstructured":"FDA Grants Orphan Drug Designation to NBM-BMX for Uveal Melanoma. https:\/\/www.novelwiseoncology.com\/data-341067."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119315_bib27","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/cmdc.201300414","article-title":"Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors","volume":"9","author":"Suzuki","year":"2014","journal-title":"ChemMedChem"},{"issue":"22","key":"10.1016\/j.ejmech.2026.119315_bib28","doi-asserted-by":"crossref","first-page":"10000","DOI":"10.1021\/acs.jmedchem.8b01087","article-title":"Characterization of histone deacetylase 8 (HDAC8) selective inhibition reveals specific active site structural and functional determinants","volume":"61","author":"Marek","year":"2018","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119315_bib29","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12964-018-0231-4","article-title":"Overexpressed HDAC8 in cervical cancer cells shows functional redundancy of tubulin deacetylation with HDAC6","volume":"16","author":"Vanaja","year":"2018","journal-title":"Cell Commun. Signal."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119315_bib30","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.ncrna.2024.02.009","article-title":"MicroRNA-mediated epigenetic regulation of HDAC8 and HDAC6: functional significance in cervical cancer","volume":"9","author":"Naik","year":"2024","journal-title":"Noncoding RNA Res"},{"issue":"22","key":"10.1016\/j.ejmech.2026.119315_bib31","doi-asserted-by":"crossref","first-page":"8828","DOI":"10.3390\/ijms21228828","article-title":"Structure\u2013Based inhibitor discovery of class I histone deacetylases (HDACs)","volume":"21","author":"Luo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"17","key":"10.1016\/j.ejmech.2026.119315_bib32","doi-asserted-by":"crossref","first-page":"18216","DOI":"10.1021\/acs.jmedchem.5c00479","article-title":"Improved pharmacokinetic profiles of HDAC6 inhibitors via cap group modifications","volume":"68","author":"Olaoye","year":"2025","journal-title":"J. Med. Chem."},{"issue":"15","key":"10.1016\/j.ejmech.2026.119315_bib33","doi-asserted-by":"crossref","first-page":"6992","DOI":"10.1021\/acs.jmedchem.9b00390","article-title":"Design, synthesis, and biological evaluation of 4-Methyl quinazoline derivatives as anticancer agents simultaneously targeting phosphoinositide 3-Kinases and histone deacetylases","volume":"62","author":"Zhang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119315_bib34","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ejmech.2018.03.075","article-title":"Synthesis and biological evaluation of 2,6-disubstituted-9H-purine, 2,4-disubstituted-hieno[3,2-d]pyrimidine and -7H-pyrrolo[2,3-d] pyrimidine analogues as novel CHK1 inhibitors","volume":"151","author":"Tian","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119315_bib35","article-title":"Thienopyrimidine and furanopyrimidine modulators of the histamine H4 receptor","author":"Edwards","year":"2011","journal-title":"China Patent CN101998958A"},{"key":"10.1016\/j.ejmech.2026.119315_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103796","article-title":"Design, synthesis and biological evaluation of novel 2,4\u2013bismorpholinothieno[3,2-d]pyrimidine and 2-morpholinothieno[3,2-d] pyrimidinone derivatives as potent antitumor agents","volume":"99","author":"Ye","year":"2020","journal-title":"Bioorg. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119315_bib37","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119315_bib38","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1080\/10428190802353591","article-title":"Preclinical versus clinical drug combination studies","volume":"49","author":"Chou","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ejmech.2026.119315_bib39","article-title":"Boltz\u20132: towards accurate and efficient binding affinity prediction","author":"Passaro","year":"2025","journal-title":"Preprint. bioRxiv."},{"issue":"15","key":"10.1016\/j.ejmech.2026.119315_bib40","doi-asserted-by":"crossref","first-page":"7835","DOI":"10.1021\/acs.jcim.5c01063","article-title":"Recent developments in amber biomolecular simulations","volume":"65","author":"Case","year":"2025","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.119315_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116425","article-title":"Design, synthesis, and biological evaluation of novel benzimidazole derivatives as anti-cervical cancer agents through PI3K\/Akt\/mTOR pathway and tubulin inhibition","volume":"271","author":"Li","year":"2024","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426007609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426007609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:24:06Z","timestamp":1792643046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426007609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":41,"alternative-id":["S0223523426007609"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119315","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and screening of novel thienopyrimidine derivatives as PI3K\/HDAC dual inhibitors against cervical cancer cells","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119315","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119315"}}